Epigenomics to Identify, Analyze Biomarkers for J&J Cancer Program

Aug 07, 2006

NEW YORK (GenomeWeb News) - Epigenomics will use its differential methylation hybridization chip to help Johnson & Johnson Pharmaceutical Research & Development identify and analyze biomarkers for potential cancer drugs.

Terms of the agreement call for Epigenomics to receive an undisclosed upfront payment under the agreement.

Additional financial details were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

A Mammoth Competition

Labs in the US and South Korea are hoping to bring the woolly mammoth back from beyond extinction, Newsweek writes.

Genetic History, Diversity

Geneticist Adam Rutherford speaks with National Geographic about paleogenetics, race, and more.

To Long Life

Researchers link genetic links between education and smoking and longevity.

This Week in PNAS

In PNAS this week: influence of gene environment interactions on polygenic traits, epigenetic features affecting fruit fly foraging, and more.

Featured White Papers

Optimized NGS Library Preparation with Acoustic Liquid Handling

Main menu